US2002006896A1PendingUtilityA1
Regulaton of cytokine synthesis and release
Priority: Jun 7, 1995Filed: Apr 27, 2001Published: Jan 17, 2002
Est. expiryJun 7, 2015(expired)· nominal 20-yr term from priority
A61K 38/57
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of treatment and prevention of diseases associated with release of neutrophil elastase and IL-8 by administration of TFPI, and analogs of TFPI are disclosed. Methods of determining efficacy of treatment with TFPI, patient's responsiveness to treatment with TFPI and the ultimate determination of patient prognosis are also disclosed.
Claims
exact text as granted — not AI-modified1 . A method of treating a disease selected from the a group consisting of:
(a) severe acute pancreatitis; (b) emphysema; (c) rheumatoid arthritis;
(d) multiple organ failure; and
(e) cystic fibrosis;
comprising the step of:
administering an effective amount of an agent to a patient displaying symptoms of said disease, wherein the agent is a protein whose sequence is at least 95% identical to the sequence of TFPI or ala-TFPI, whereby one or more symptoms of the disease is improved.
2 . The method of claim 1 wherein the agent is a protein whose sequence is at least 98% identical to the sequence of TFPI.
3 . The method of claim 1 wherein the agent is a protein which differs from TFPI in having a one amino acid residue substitution.
4 . The method of claim 1 wherein the agent is ala-TFPI.
5 . The method of claim 1 wherein the agent is TFPI.
6 . The method of claim 1 wherein the agent is a protein which is at least 95% identical by sequence to ala-TFPI, whereby one or more symptoms of the disease is improved.
7 . The method of claim 1 wherein the agent is a protein which is at least 98% identical by sequence to ala-TFPI.
8 . The method of claim 1 wherein the agent is a protein which differs from ala-TFPI in having a one amino acid residue substitution.
9 . The method of claim 1 wherein the disease is emphysema.
10 . The method of claim 2 wherein the disease is emphysema.
11 . The method of claim 3 wherein the disease is emphysema.
12 . The method of claim 4 wherein the disease is emphysema.
13 . The method of claim 5 wherein the disease is emphysema.
14 . The method of claim 6 wherein the disease is emphysema.
15 . The method of claim 7 wherein the disease is emphysema.
16 . The method of claim 8 wherein the disease is emphysema.
17 . The method of claim 1 wherein the agent is rheumatoid arthritis.
18 . The method of claim 2 wherein the agent is rheumatoid arthritis.
19 . The method of claim 3 wherein the agent is rheumatoid arthritis.
20 . The method of claim 4 wherein the agent is rheumatoid arthritis.
21 . The method of claim 5 wherein the agent is rheumatoid arthritis.
22 . The method of claim 6 wherein the agent is rheumatoid arthritis.
23 . The method of claim 7 wherein the agent is rheumatoid arthritis.
24 . The method of claim 8 wherein the agent is rheumatoid arthritis.
25 . The method of claim 1 wherein the agent is multiple organ failure.
26 . The method of claim 2 wherein the agent is multiple organ failure.
27 . The method of claim 3 wherein the agent is multiple organ failure.
28 . The method of claim 4 wherein the agent is multiple organ failure.
29 . The method of claim 5 wherein the agent is multiple organ failure.
30 . The method of claim 6 wherein the agent is multiple organ failure.
31 . The method of claim 7 wherein the agent is multiple organ failure.
32 . The method of claim 8 wherein the agent is multiple organ failure.
33 . The method of claim 1 wherein the agent is cystic fibrosis.
34 . The method of claim 2 wherein the agent is cystic fibrosis.
35 . The method of claim 3 wherein the agent is cystic fibrosis.
36 . The method of claim 4 wherein the agent is cystic fibrosis.
37 . The method of claim 5 wherein the agent is cystic fibrosis.
38 . The method of claim 6 wherein the agent is cystic fibrosis.
39 . The method of claim 7 wherein the agent is cystic fibrosis.
40 . The method of claim 8 wherein the agent is cystic fibrosis.
41 . A method of preventing at least one symptom of a disease selected from the group consisting of:
(a) severe acute pancreatitis; (b) emphysema; (c) rheumatoid arthritis; (d) multiple organ failure; and (e) cystic fibrosis; comprising the step of:
administering an effective amount of an agent to a patient at risk of developing a symptom associated with said disease or contracting said disease, wherein the agent is a protein which is at least 95% identical by sequence to TFPI or ala-TFPI, whereby the risk of developing the symptom is reduced.
42 . The method of claim 41 wherein the agent is a protein which is at least 98% identical by sequence to TFPI.
43 . The method of claim 41 wherein the agent is a protein which differs from TFPI in having a one amino acid residue substitution.
44 . The method of claim 41 wherein the agent is ala-TFPI.
45 . The method of claim 41 wherein the agent is at least 95% identical by sequence to ala-TFPI.
46 . The method of claim 41 wherein the agent is a protein which is at least 98% identical by sequence to ala-TFPI.
47 . The method of claim 41 wherein the agent is a protein which differs from ala-TFPI in having a one amino acid residue substitution.
48 . The method of claim 41 wherein the agent is TFPI.Join the waitlist — get patent alerts
Track US2002006896A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.